相互作用
Encorafenib + Netupitant-palonosetron
重症度: 重大
Encorafenib and Netupitant-palonosetron: major interaction.
最終更新日
医療従事者向け・参照専用。このページは簡潔な要約であり、医学的助言ではなく、公式の添付文書や臨床判断に代わるものではありません。処方・調剤の前に必ず確認してください。
このページの臨床コンテンツは英語でのみ提供されています。
概要
Netupitant raises encorafenib exposure through CYP3A4 inhibition, increasing the risk of toxicities including QT prolongation. Encorafenib labeling advises avoiding moderate inhibitors or reducing the dose.
この相互作用をわかりやすく説明すると
Encorafenib and Netupitant-palonosetron can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Encorafenib belongs to Oncology; Netupitant-palonosetron belongs to Gastrointestinal Tract.
なぜ起こるのか
CYP3A4 inhibition by netupitant decreases encorafenib clearance.
対処法
Use an alternative antiemetic if possible. If unavoidable, reduce encorafenib to the labeled dose and monitor ECG and electrolytes.
薬剤師に尋ねること
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+会員向け
ページ全体を見る
アカウントを作成してPro+トライアルを始めると、EncorafenibとNetupitant-palonosetronの臨床対応の詳細なアドバイス、追加の注記、エビデンスの詳細、処方全体を対象とした相互作用チェッカーを利用できます。
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
WebでPro+を14日間無料でお試し。カード登録不要。
Netupitant-palonosetronのその他の相互作用
Encorafenibのその他の相互作用
よくある質問
Can I take Encorafenib with Netupitant-palonosetron?
MediHelp rates the interaction as major. Encorafenib and Netupitant-palonosetron can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Netupitant raises encorafenib exposure through CYP3A4 inhibition, increasing the risk of toxicities including QT prolongation. Encorafenib labeling advises avoiding moderate inhibitors or reducing the dose.
How serious is the interaction between Encorafenib and Netupitant-palonosetron?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Use an alternative antiemetic if possible. If unavoidable, reduce encorafenib to the labeled dose and monitor ECG and electrolytes.
What other medicines interact with Netupitant-palonosetron?
MediHelp also lists interactions of Netupitant-palonosetron with, for example, Apomorphine, Flibanserin, Apalutamide. The full list is on the Netupitant-palonosetron page.
完全なモノグラフ、用量、相互作用チェッカーはMediHelpアプリで
MediHelpアプリで、完全なリファレンスを開き、複数薬剤の相互作用をチェックし、用量ツールを利用できます。
